The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Treatment sequencing as BCMA-targeted therapies move into earlier lines
Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ and International Myeloma Foundation, Studio City, CA, discusses treatment sequencing as BCMA-targeted therapies move into earlier lines of multiple myeloma treatment. He highlights the importance of selecting the most appropriate therapy based on individual patient factors rather than reserving specific modalities, noting that CAR-T therapy, bispecific antibodies and antibody-drug conjugates (ADCs) may remain options across subsequent lines. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
